Viemed Healthcare opened at $9.13, in line with its previous close of $9.13. In the last trading session, the stock traded between $9.04 and $9.22. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Viemed Healthcare is now worth
$ 158.50
Giving a profit of
$ 58.50 (58.50%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
50%
Hold
50%
Sell
0%
Markets Today
Today's Change
$-0.02 (-0.18%)
Day High
$9.22
Day Low
$9.04
Day Open
$9.13
Prev Close
$9.13
Volume
1,29,464
1W Return
-9.73%
1M Return
-5.15%
3M Return
-1.79%
6M Return
0.93%
1Y Return
43.53%
Fundamentals
Market Cap ($ Mn)
345
PE Ratio
24.50
PB Ratio
2.33
PEG Ratio
4.14
ROE
11.29%
ROCE
15.38%
EPS (TTM)
$0.12
Investment Returns
1 Week
-9.73%
1 Month
-5.15%
3 Months
-1.79%
6 Months
0.93%
9 Months
7.86%
Financials
Quarterly
All values in $ Mn
63.1
Jun 25
71.9
Sep 25
76.2
Dec 25
75.4
Mar 26
78.1
Jun 26
80.7
Sep 26
Updates
5Nov
Viemed Healthcare raises FY26 sales guidance to $316M-$320M
Viemed Healthcare raises FY26 sales guidance lower bound to $316 million. New guidance range is $316 million-$320 million, up from $314 million-$320 million. Revised outlook exceeds the analyst estimate of $317.937 million.
8 days ago
25Sep
Viemed Healthcare president adopts plan to sell 246,000 shares
Michael Moore, President of Viemed Healthcare, adopted an ASDP to sell up to 246,000 common shares. The sale period extends through November 30, 2027, with earliest sales starting December 24, 2026. The proposed sale represents less than 11% of Moore's total beneficial ownership in the company.
1mo ago
4Aug
Viemed Healthcare raises FY26 sales guidance to $314-320M
Viemed Healthcare Inc. raised its FY2026 sales guidance from $312.000M-$320.000M to $314.000M-$320.000M. The revised outlook exceeds the $317.300M analyst estimate, reflecting strong demand visibility.
3mo ago
4Aug
Viemed Healthcare Q2 EPS misses $0.12 estimate on $78.1M revenue
Viemed Healthcare's Q2 2026 EPS of $0.07 missed analyst estimates of $0.12 by 41.67%, while sales of $78.097 million narrowly missed estimates. Despite the profit miss, revenue grew 23.85% YoY, driven by record patient volumes in ventilation and PAP therapy.
Viemed Healthcare, Inc. announced the scheduling of its Second Quarter 2026 Earnings Conference Call for August 4, 2026, at 11:00 a.m. EDT. The company provided specific dial-in numbers for US and international participants, alongside a live webcast option. A replay of the event will be hosted on the Investor Relations section of its website.
